Abstract
Sacubitril/valsartan, a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI), is indicated for the treatment of heart failure with reduced ejection fraction. It has demonstrated benefits in terms of cardiovascular morbidity and mortality reduction in this population. Recently, this drug association has also been shown to improve glycemic control and insulin sensitivity in patients with obesity and/ or type 2 diabetes. Furthermore, some studies suggest a protective role of this new drug class in diabetic nephropathy. Altogether, these data raise the question about the potential place of ARNI in prevention and treatment of type 2 diabetes, a condition closely associated with heart failure.
| Translated title of the contribution | Potential role of sacubitril/valsartan combination in type 2 diabetes |
|---|---|
| Original language | French |
| Pages (from-to) | 1418-1422 |
| Number of pages | 5 |
| Journal | Revue Medicale Suisse |
| Volume | 17 |
| Issue number | 747 |
| State | Published - 25 Aug 2021 |
| Externally published | Yes |